

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :  A61K 31/70, 31/60, 31/495, 31/40, 31/195, 31/19, 31/17		A1	(11) International Publication Number: WO 00/51620  (43) International Publication Date: 8 September 2000 (08.09.00)
(21) International Application Number: PCT/US00/05587  (22) International Filing Date: 2 March 2000 (02.03.00)  (30) Priority Data: 60/122,503 2 March 1999 (02.03.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant: VITREO-RETINAL TECHNOLOGIES, INC. [US/US]; Suite 307, 480 Fourth Avenue, Chula Vista, CA 91910 (US).  (72) Inventor: CASTILLEJOS, David; Suite 307, 480 Fourth Avenue, Chula Vista, CA 91910 (US).  (74) Agents: BUYAN, Robert, D. et al.; Stout, Uxa, Buyan & Mullins, LLP, 4 Venture #300, Irvine, CA 92618 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE

(57) Abstract

Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing (a) urea, (b) urea derivatives (e.g., hydroxyurea, thiourea), (c) a non-steroidal anti-inflammatory agent, (d) antimetabolites, (e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytidine, guanine, guanidine, guanidinium, thymidine, thimidine, uridine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or (e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT  
OR PREVENT DISORDERS OF THE EYE**

**FIELD OF THE INVENTION**

5       The present invention relates generally to pharmaceutical preparations and medical treatment methods, and more particularly agents (i.e., urea and urea derivatives, nonsteroidal anti-inflammatory drugs (NSAIDS) and anti -metabolite drugs) used alone or in combinations with each other (or with other agents) to treat or prevent certain disorders of the eye.

10      **BACKGROUND OF THE INVENTION**

**A. Neovascularization**

Neovascularization (or angiogenesis) is a process whereby new blood vessels are formed within tissues of the body. *Normal* neovascularization is the physiological process by which the body creates and maintains small blood vessels of the circulatory system.

15     However, *pathological* or *iatrogenic* neovascularization is a non-physiological process whereby abnormal networks of blood vessels are created in tissues of the body or in tumors, as a result of certain diseases, trauma or surgical procedures.

Pathological neovascularization occur within tissues of the eye as a result of certain ophthalmic disorders such as diabetic retinopathies, proliferative vitreoretinopathies, corneal neovascularization, iris rubeosis, and diseases that cause ischemia of the ocular tissues (e.g., occlusion of the central retinal vein, occlusion of the central retinal artery, certain inflammatory conditions, etc.). Also, iatrogenic neovascularization can occur following certain ophthalmological surgical procedures which disrupt normal blood supply to tissues of the eye or those which cause localized proliferations of cells known as "fibroblasts".

20     Examples of ophthalmological surgical procedured that have been associated with untoward post-surgical neovascularization include glaucoma filtration surgery and corneal transplant surgery.

Various types of drugs and agents (e.g., steroids, non-steroidal anti-inflammatory drugs (NSAIDS), heparin, protamine, calcitrol, antibiotics, thrombospondin fragments, and 30 monoclonal antibodies directed to fibroblast growth factor) have been purported to be useable to treat or prevent neovascularization of the anterior segment of the eye. Non steriodal anti-inflammatory drugs have not been used to treat neovascularization of the posterior segment of the eye.

Also, laser surgical procedures have been used to ablate or destroy neo-vascular networks which develop in the retina or epiretinal membranes. However, these prior therapies for ocular neovascularization have been less than completely effective and/or have been associated with side effects. For example, glucocorticoids and other angiostatic 5 steroids have been used to treat neovascularization of the anterior chamber (e.g., corneal neovascularization, iris rubeosis) and/or other ocular tissues, but such steroid treatments have been associated with side effects such as elevated intraocular pressure. see, Kitazawa, *Increased Intraocular Pressure Induced by Corticosteroids*, American Journal of Ophthalmology, Vol. 82, Pg.492-493 (1976)

10

**B. Intravitreal Hemorrhage and the Need for Liquefaction of the Vitreous Body and/or Posterior Vitreous Dissinsertion or Detachment Prior to Vitrectomy:**

In many mammals including human beings, the "vitreous body" is disposed within a posterior portion of the eye and occupies approximately four fifths of the cavity of the eyeball, 15 behind the lens. The vitreous body is formed of gelatinous material, known as the vitreous humor. The vitreous humor of a normal human eye is made up of approximately 99% water along with 1% macromolecules including; collagen, hyaluronic acid, soluble glycoproteins, sugars and other low molecular weight metabolites.

The retina is essentially a layer of nervous tissue which covers a portion of the inner 20 wall of the posterior segment—in juxtaposition to the posterior aspect of the vitreous body. The retina is surrounded by a layer of cells known as the choroid layer. The retina may be divided into a) an optic portion which participates in the visual mechanism, and b) a non-optic portion which does not participate in the visual mechanism. The optic portion of the retina contains the rods and cones, which are the effectual organs of vision. A number of arteries 25 and veins enter the retina at its center, and splay outwardly to provide blood circulation to the retina.

The posterior portion of the vitreous body is in direct contact with the retina. Networks of fibrillar strands extend from the retina and permeate or insert into the vitreous body so as to attach the vitreous body to the retina.

30 Diabetic retinopathy, trauma and other ophthalmological disorders sometimes result in rupture or leakage of retinal blood vessels with resultant bleeding into the vitreous humor of the eye (i.e., "intravitreal hemorrhage). Such intravitreal hemorrhage typically manifests as clouding or opacification of the vitreous humor.

Intravitreal hemorrhage is sometimes, but not always, accompanied by tearing or detachment of the retina. In cases where the intravitreal hemorrhage is accompanied by a retinal tear or detachment, it is important that such retinal tear or detachment be promptly diagnosed and surgically repaired. Failure to promptly diagnose and repair the retinal tear  
5 or detachment may allow photo-receptor cells of the retina, in the region of the tear or detachment, to become necrotic. Such necrosis of the photoreceptor cells of the retina may result in loss of vision. Furthermore, allowing the retinal detachment to remain unrepairs for such extended period of time may result in further intravitreal hemorrhage and/or the formation of fibrous tissue at the site of the hemorrhage. Such formation of fibrous tissue  
10 may result in the formation of an undesirable fibrous attachment between the vitreous body and the retina.

The typical surgical procedure used for repair of retinal tears or detachment requires that the surgeon be able to look through the vitreous humor, to visualize the damaged region of the retina (i.e., "transvitreous viewing of the retina"). When intravitreal hemorrhage has  
15 occurred, the presence of the hemorrhagic blood within the vitreous can cause the vitreous to become so cloudy that the surgeon is prevented from visualizing the retina through the vitreous. Such hemorrhagic clouding of the vitreous can take 6-12 months or longer to clear sufficiently to permit trans-vitreous viewing of the retina. However, in view of the potential complications which may result from delayed diagnosis or treatment of a retinal tear or  
20 detachment, it is generally not desirable to wait for such natural clearance of the hemorrhagic blood to occur.

Furthermore, even when the intravitreal hemorrhage is not accompanied by retinal tear or detachment, it is often difficult to verify that retinal tear or detachment has not occurred, because the hemorrhagic clouding of the vitreous prevents the physician from  
25 performing routine funduscopic examination of the retina. Moreover, the presence of hemorrhagic blood within the vitreous may significantly impair the patient's vision through the affected eye, and will continue to do so until such time as the hemorrhagic blood has been substantially or fully cleared.

Thus, the presence of hemorrhagic blood within the vitreous body causes multiple  
30 clinical problems including a) inability to visually examine and diagnose the site of the hemorrhage and/or any accompanying tear or detachment of the retina, b) full or partial impairment of vision in the affected eye and c) impairment or prevention of the performance of trans-vitreous surgical procedures of the type typically utilized to repair the site of hemorrhage and/or to repair any accompanying retinal tear or detachment. In cases where

intravitreal hemorrhage has resulted in substantial clouding or opacification of the vitreous, the treating physician may have the option to perform a procedure known as a vitrectomy, wherein all (or a portion of) the vitreous body is removed from the interior of the eye, and replaced with a clear liquid or gas. The performance of such vitrectomy procedure is  
5 intended to allow the surgeon to visualize the retina sufficiently to proceed with the necessary retinal examination and/or surgical repair of the hemorrhage and any accompanying retinal tear or detachment. However, such vitrectomy procedures are highly skill-intensive, and are associated with several significant drawbacks, risks and complications. Among these drawbacks, risks and complications are the potential that the  
10 act of removing the vitreous will cause further detachment or tearing of the retina and/or that such removal of the vitreous will cause further hemorrhage from the already-weakened retinal blood vessels. In order to minimize the stress of tugging on the retina during vitrectomy and to otherwise facilitate the removal of the vitreous body, it is sometimes desirable to precede the vitrectomy by the intravitreal injection of a substance which will  
15 cause liquefaction of the vitreous humor and/or disinsertion/detachment of the vitreous humor from the adjacent tissues of the retina and epiretinal membranes. Examples of substances which have been purported to cause vitreal liquefaction and/or posterior vitreous detachment/disinsertion are found in United States Patent Nos. 4, 820, 516 (Sawyer), 5,292,509 (Hageman) and 5, 866, 120 (Karageozian et al.).

20

**C. Prior Ophthalmic Applications of Urea and Urea Derivatives:**

United States Patents No. 5,629,344 (Charlton et al.) has described the topical application to the cornea or "surface" of the eye of urea and/or urea derivative(s) to treat ocular conditions such as dryness, non-infectious keratitis, irregularities of the corneal or  
25 conjunctival epithelium, ocular scarring and "subjective irritations" as well as to inhibit unwanted fibroblast formation and/or enhance healing following glaucoma, cataract and corneal surgeries.

**D. Prior Ophthalmic Applications of Non-Steroidal Anti-Inflammatory Agents:**

30 Several NSAIDS have heretofore been known for oral administration and/or topical application to the eye for the purpose of treating inflammatory conditions of the eye and/or post surgical pain and inflammation of the anterior segment of the eye. Examples of NSAIDS that are presently available for topical application to the eye include diclofenac (Cataflam), flurbiprofen (Ansaid), ketorolac (Toradol, Acular). To date, ophthalmic NSAID preparations

have been used primarily to treat inflammatory disorders of the cornea and anterior segment of the eye. In instances where ophthalmic NSAIDS have been administered to treat disorders of the posterior segment of the eye, the NSAID has been initially applied to the anterior segment of the eye with the intention that a therapeutic amount of the NSAID will 5 distribute from the anterior segment to the posterior segment of the eye where the therapeutic effect is desired. For example, Acular<sup>TM</sup> (ketorolac) drops have been applied topically to the anterior segment of the eye (i.e., to the cornea) for the purpose of treating cystoid macular edema--a disorder of the posterior segment of the eye.

10        **E. Prior Ophthalmic Applications of Anti-Metabolites:**

5-Fluorouracil and Mitomicin C have previously been purported to be useable, when administered to the anterior segment of the eye, to inhibit or treat certain conditions of the anterior segment that are characterized by undesired tissue proliferation such as benign fibrovascular lesions of the conjunctiva known as Pterygia.

15

**SUMMARY OF THE INVENTION**

The method of the present invention generally comprises the step of delivering into the eye (e.g., by intravitreal injection or instillation into the posterior segment of the eye) a therapeutically effective amount of an agent selected from the following:

- 20        a) urea  
              b) urea derivatives (e.g., hydroxyurea, thiourea);  
              c) a non-steroidal anti-inflammatory agent;  
              d) an antmetabolite;  
              e) a urea, urea derivative, non-enzymatic protein urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytidine, guanine, guanitidine, guanidinium, thymidine, thimidine, uridine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane; and,  
25  
              f) any of the possible combinations thereof.
- 30

The method of the present invention is carried out for the purpose of bringing about one or more of the following effects:

- causing non-exzymatic dissolution of the hyaloid interface (i.e.,

- hyaloid membrane) or other proteins or amino acids responsible for maintaining attachment between the vitreous body and retina of a mammalian eye, or otherwise inducing posterior vitreous detachment and/or disinsertion of the vitreous body from the retina and epiretinal membranes (hereinafter referred to as "PWD");
- causing liquefaction of the vitreous humor;
  - causing diffusion or preventing the accumulation of localized concentrations near the retina of substances that are injurious or pathogenic to the retina (e.g., angiogenic factors);
- causing dissolution of coagulum within the vitreous humor (as may occur following intravitreal hemorrhage);
- causing a solvent action on fibroblasts;
  - inhibiting fibroblasts;
  - inhibiting or preventing fibrosis associated with the presence of vitreous heme;
  - inhibiting the proliferation of fibroblasts in ocular tissues; and,
  - causing reactivation (e.g., regeneration, regrowth, stimulation, up-regulation or improved neuronal transmission) of inactive nerves or nerve fibers (e.g., optic nerve).
- By one or more of the above-listed effects, or by other mechanisms, the method of the present invention is useable for various therapeutic and/or prophylactic applications, including but not limited to:
- treating (e.g., as used herein "treating" shall mean preventing, deterring, stopping, curing or slowing the progression of) diabetic retinopathy;
  - treating intravitreal hemorrhage and accelerating the clearance of hemorrhagic blood from the vitreous humor;
  - inducing PVD and/or liquefaction of the vitreous prior to the performance of a vitrectomy thereby limiting the likelihood of retinal detachment, retinal tearing, re-stimulation of retinal hemorrhage or other complications of the vitrectomy procedure;
  - treating vitreous traction associated with macular holes;
  - treating macular degeneration;
  - treat retinitis pigmentosa;
  - prophylaxis to retinal detachment in patients who are at high risk for

- retinal detachment (e.g., high myopes);
- treating preretinal and subretinal membranes;
  - treating cystoid macular edema;
  - pre-operative preparation of the eye in the surgical treatment of eye  
5 trauma;
  - pre-operative treatment prior to certain types of glaucoma surgery  
(e.g., those performed for the treatment of neovascular glaucoma);
  - treating occlusion of the central retinal vein or central retinal artery;
  - treating conditions associated with neovascularization such as  
10 neovascular iris and neovascular glaucoma;
  - treating ocular ischemic syndrome;
  - treating conditions associated with posterior eye inflammation such as  
VKH, pars planitis, toxoplasmosis, etc.; and,
  - improving the delivery and bioavailability to the retina and other  
15 tissues of intravitreally administered drugs;
  - treating pterygia (e.g., loxopterygium, pimelopterygium,  
symblepharopterygium);
  - treating stromal-corneal neovascularization;
  - treating glaucoma blebs;
  - treating optic nerve atrophy or impaired optic nerve activity of any  
20 cause; and,
  - treating glaucoma-induced cupping of the optic nerve.

Further in accordance with the invention, the urea and urea derivative agents useable in the method comprise urea, hydroxyurea and thiourea.

25 Still further in accordance with the invention, the agents of the present invention may be administered by injection into the eye (e.g., intravitreal, intrastromal or sub-conjunctival injection).

Still further in accordance with the invention, the non-steroidal anti-inflammatory drugs that are most suitable for use in the method of the present invention include the  
30 heteroaryl acetic acids (e.g., tolmetin, diclofenac, ketorolac) and the arylpropionic acids (e.g., ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin). Combination of an NSAID with urea or a urea-containing compound is particularly useable for the treatment of posterior inflammatory conditions such as VKH, pars planitis, toxoplasmosis, etc.

Still further in accordance with the invention, the anti-metabolite compounds that are useable in the method comprise, mitomycin C, methotrexate, thiourea, hydroxyurea, 6-mercaptopurine, thioguanine, 5-fluorouracil, cytosine arabinoside and 5-azacytidine. (Thiourea and hydroxyurea are anti-metabolites as well as urea derivatives.) Other anti-  
5 neoplastic compound such as Actinomycin D, daunorubicin, doxorubicin, idarubicin, bleomycins, or plicamycin may also be used in combination with these anti-metabolites. Combinations of these anti-metabolite agents (or other anti-neoplastic drugs) with urea or  
10 a urea-containing compounds are particularly useable for the treatment of Intraocular tumors, posterior uveitis, wet macular degeneration, age related macular degeneration (dry form), retinitis pigmentosa, retina of prematurity (ROP), retinal vasculitis (e.g., secondary to Eales disease, lupus retinopathy, sarcoidosis, etc.), neovascular glaucoma, phacomorphic reactions and sympathetic ophthalmia.

Still further in accordance with the invention, PVD may be induced by the administration (e.g. intravitreal injection) of therapeutically effective amount(s) of one or more  
15 agents that cause non-enzymatic dissolution of the hyaloid membrane or hyaloid interface. As a result of such hyaloid dissolution, the vitreous body will become detached or disinserted from the retina, thereby allowing vitrectomy, repair of retinal tears, or other procedure to be performed with lessened chance for inducing retinal tearing or retinal hemorrhage. For example, in many traditional vitrectomy procedures, the tugging or cutting away of the  
20 vitreous body can result in tearing or damage to the retina because the hyaloid interface remains in tact. Also, after the vitreous body has been substantially removed using a vitrectomy cutter, the physician must (in many cases) peel the remaining hyaloid membrane away from the retina. Such peeling away of the hyaloid from the retina can further cause retinal tearing or damage. Thus, by administering one or more compounds capable of  
25 causing non-enzymatic dissolution of the hyaloid membrane, PVD may be induced and such potential for iatrogenic damage to the retina will be minimized. Examples of agents that may be administered by intravitreal injection to cause such non-enzymatic dissolution of the hyaloid membrane include urea, urea derivatives, urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine,  
30 cytidine, guanine, guanitidine, guanidinium, thymidine, thimididine, uridine, uracil, cystine), uric acid, calcium acetal salicylate and ammonium sulfate.

Still further aspects, objects and advantages of the invention will be apparent to those of skill in the art who read and understand the following detailed description of the invention and the specific examples set forth therein.

### DETAILED DESCRIPTION OF THE INVENTION

- As summarized hereabove, the present invention provides urea containing solutions (i.e., solutions which contain urea, a urea derivative (e.g., hydroxyurea) and/or mixtures thereof) that are injectable into the eye alone, non-steroidal anti-inflammatory drugs 5 (NSAIDS) injected into the eye alone and anti-metabolites that are injected into the eye alone. Additionally, the some of the urea-containing or injectable solutions of the present invention may further contain non-steroidal anti-inflammatory agent(s) (e.g., flurbiprofen, diclofenac, ketorolac) and/or antimetabolite(s) (e.g., mitomycin C, methotrexate, 6-mercaptopurine, thioguanine, 5-fluorouracil, cytosine arabinoside and 5-azacytidine).
- 10 Solutions of urea or hydroxyurea, which have been adjusted to a pH of approximately 4.0 to 7.0, are substantially non-toxic and well tolerated when injected intravitrially, subconjunctively or intrastromally, one (1), two (2) or more times, in an injectate volume of 50-100 microliters per injection, at doses of 33-5000 micrograms of urea per injection.

15 **A. Urea Formulations**

The following are examples of urea-containing solutions that are useable in accordance with this invention:

**Example 1**

20	Urea USP/NF	4.0%
	Sodium Chloride USP/NF	up to 0.9%
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
(Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide)		

25

**Example 2**

30	Urea USP/NF	4.0%
	Citric Acid USP/NF	0.00007-0.02%
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
(Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide)		

**Example 3**

	Urea USP/NF	0.01% - 15.0%
	Sodium Chloride USP/NF	up to 0.9%
	Sterile Water for Injection USP	Q.S. 100%
5	pH of solution	5.0- 7.0
	(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)	

**Example 4**

	Urea USP/NF	4.0%
10	Potassium Phosphate Dibasic USP/NF	5.0 millimolar
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
	(Adjust pH using 0. 1 N Hydrochloric acid/ 0. 1 N Sodium Hydroxide)	

**Example 5**

	Urea USP/NF	4.0%
	Potassium Phosphate Dibasic USP/NF	50.0 millimolar
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
20	(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)	

**Example 6 (Lyophilized Powder)**

	Urea USP/NF	0.01%-15.0%
	Sorbitol USP/NF	0.10%-0.50%
25	Citric Acid USP/NF	0.00007-0.02%
	pH of final solution	5.0- 7.0
	(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)	

**Example 7**

	Urea USP/NF	4.0%
	Sorbitol USP/NF	0.10%
	Citric Acid USP/NF	0.00007-0.02%
	pH of final solution	5.0- 7.0
	(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)	

Citrate or phosphate buffers may alternatively be used in the above-listed formulations of Examples 1-7. Also, sodium chloride and dextrose are alternative bulking agents that could be used in the lyophilized formulation of Example 6.

5           **B. Urea-Enzyme Solutions**

The following are examples of formulations wherein urea is combined with another agent, such as an enzyme.

**Example 8**

10	Urea USP/NF	4.0 %
	Hyaluronidase	1.0 IU- 100 IU
	Sodium Chloride USP/NF	up to 0.9 %
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
15	(Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide)	

**Example 9**

20	Urea USP/NF	0.01 % -15.0 %
	Hyaluronidase	1.0 IU- 100 IU
	Sodium Chloride USP/NF	up to 0.9 %
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
	(Adjust pH using 0. 1 N Hydrochloric acid/ 0. 1 N Sodium Hydroxide)	

25           **Example 10**

30	Urea USP/NF	0.01 % -15.0 %
	Urokinase	1.0 IU- 50 IU
	Sodium Chloride USP/NF	up to 0.9 %
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
	(Adjust pH using 0. 1 N Hydrochloric acid/ 0. 1 N Sodium Hydroxide)	

**Example 11**

Urea USP/NF	0.01 % -15.0 %
-------------	----------------

	Chondroitinase A B C	1.0 IU- 30 IU
	Sodium Chloride USP/NF	up to 0.9 %
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
5	(Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide).	

**Example 12**

	Hydroxy Urea	0.01 % - 15.0 %
	Hyaluronidase .	1.0 IU- 100 IU
10	Sodium Chloride USP/NF	up to 0.9 %
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
	(Adjust pH using 0. 1 N Hydrochloric acid/ 0. 1 N Sodium Hydroxide)	

**15      C.    Hydroxy Urea Solutions**

The following are examples of hydroxy urea-containing formulations useable in accordance with the present invention.

**Example 13**

20	Hydroxy Urea	4.0%
	Sodium Chloride USP/NF	up to 0.9%
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	5.0- 7.0
	(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)	

25

**Example 14**

	Hydroxy Urea	4.0%
	Citric Acid USP/NF	0.00007-0.02%
	Sterile Water for Injection USP	Q.S. 100%
30	pH of solution	5.0- 7.0
	(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)	

**Example 15**

Hydroxy Urea	0.01% - 15.0%
--------------	---------------

Sodium Chloride USP/NF up to 0.9%  
 Sterile Water for Injection USP Q.S. 100%  
 pH of solution 5.0- 7.0  
 (Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)

5

**Example 16**

Hydroxy Urea 4.0%  
 Potassium Phosphate Dibasic USP/NF 5.0 millimolar  
 Sterile Water for Injection USP Q.S. 100%  
 10 pH of solution 5.0- 7.0  
 (Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide)

**Example 17**

Hydroxy Urea 4.0%  
 Potassium Phosphate Dibasic USP/NF 50.0 millimolar  
 Sterile Water for Injection USP Q.S. 100%  
 pH of solution 5.0- 7.0  
 (Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide)

20 **Example 18 ( Lyophilized Powder)**

Hydroxy Urea 0.01% - 15.0%  
 Sorbitol USP/NF 0.10% - 0.50%  
 Citric Acid USP/NF 0.00007-0.02%  
 pH of final solution 5.0- 7.0  
 25 (Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide)

**Example 19**

Hydroxy Urea 4.0%  
 Sorbitol USP/NF 0.10%  
 30 Citric Acid USP/NF 0.00007-0.02%  
 pH of final solution 5.0- 7.0  
 (Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide)

**D. Urea-NSAID and Hydroxy Urea-NSAID Solutions**

The following are examples of formulations for Urea-NSAID and Hydroxy Urea-NSAID Solutions that are useable in accordance with the present invention.

5           **Example 20**

Flurbiprofen Sodium	0.03%
Sodium Chloride USP/NF	0.70%
Citrate buffer	5.0 - 50.0 millimolar
Sterile Water for Injection USP	Q.S. 100%
10       pH of solution	4.0 - 6.0
	(Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide)

**Example 21**

Flurbiprofen Sodium	0.03%
15       Urea USPNF	4.0%
Citrate buffer	5.0 - 50.0 millimolar
Sterile Water for Injection USP	Q.S. 100%
pH of solution	4.0 - 6.0
	(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)

20

**Example 22**

Flurbiprofen Sodium	0.03%
Hydroxy Urea	4.0%
Citrate buffer	5.0 - 50.0 millimolar
25       Sterile Water for Injection USP	Q.S. 100%
pH of solution	4.0 - 6.0
	(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)

**Example 23**

Flurbiprofen Sodium	0.01% - 0.03%
Urea USP/NF	0.01% - 15.0%
Citrate buffer	5.0 - 50.0 millimolar
Sterile Water for Injection USP	Q.S. 100%
pH of solution	4.0 - 6.0

(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)

**Example 24**

	Flurbiprofen Sodium	0.01% - 0.03%
5	Hydroxy Urea	0.01% - 15.0%
	Citrate buffer	5.0 - 50.0 millimolar
	Sterile Water for Injection USP	Q.S. 100%
	pH of solution	4.0 - 6.0

(Adjust pH using 0. 1 N Hydrochloric acid / 0. 1 N Sodium Hydroxide)

10 It will be appreciated that any of the above-set-forth solutions may be injected intravitreously or may be injected into other portions of the eye, to effect the therapeutic treatment(s) of the present invention.

**E. Antibetabolite Formulations:**

15 The following are examples of formulations for antimetabolite solutions that are useable in accordance with the present invention.

**Example 25**

	Hydroxyurea	0.01% - 15.0%
20	NaCl USP/NF	up to 0.9%
	Sterile Water for Injection USP	Q.S. 100%
	pH	5.0 - 7.0

(Adjust pH using 0.1 N Hydrochloric acid 0.1 N Sodium Hydroxide)

**Example 26**

	Mitomycin C	200 $\mu$ g - 200 mg
25	NaCl USP/NF	up to 0.9%
	Sterile Water for Injection	Q.S. 100%
	pH	5.5 - 7.5
30	(Adjust pH using 0.1 N Hydrochloric acid 0.1 N Sodium Hydroxide)	

(Refrigerate after compounding, stable for up to 3 days)

**Example 27**

Mitomycin C	200 $\mu$ g - 200 mg
-------------	----------------------

Sorbital USP/ NF	0.1 - 0.5%
NaCl	0.2%
(lyophilized powder)	

5           **Example 28**

Thiourea	0.01% - 10.0%
NaCl USP/NF	up to 0.9%
Sterile Water for Injection	Q.S. 100%
pH	4.0 - 6.0

10           (Adjust pH using 0.1 N Hydrochloric acid 0.1 N Sodium Hydroxide)

**F.       NSAID Formulations:**

The following are examples of formulations for NSAID solutions that are useable in accordance with the present invention.

15           **Example 29**

Flurbiprofen Sodium	0.03%
NaCl USP/NF	up to 0.9%
Citrate buffer	5 millimoles - 50 millimmoles

20           Sterile Water for Injection USP           Q.S. 100%

pH	4.0 - 6.0
----	-----------

(Adjust pH using 0.1 N Hydrochloric acid 0.1 N Sodium Hydroxide)

**Example 30**

Flubiprofen	0.01% - 0.5%
NaCl USP/NF	up to 0.9%
Citrate buffer	5 millimoles - 50 millimmoles

25           Sterile Water for Injection USP           Q.S. 100%

pH	4.0 - 6.0
----	-----------

30           (Adjust pH using 0.1 N Hydrochloric acid 0.1 N Sodium Hydroxide)

**Example 31**

Ibuprofen	0.01% - 0.5%
NaCl	0.7%

Citrate buffer                                    5 millimoles - 50 millimmoles  
 Sterile Water for Injection USP                Q.S. 100%  
 pH    4.0 - 6.0  
 (Adjust pH using 0.1 N Hydrochloric acid 0.1 N Sodium Hydroxide)

5

**Example 32**

Ketolorac                                        0.01% - 0.5%  
 NaCl    0.7%  
 Citrate buffer                                    5 millimoles - 50 millimmoles  
 10 Sterile Water for Injection USP            Q.S. 100%  
 pH    4.0 - 6.0  
 (Adjust pH using 0.1 N Hydrochloric acid 0.1 N Sodium Hydroxide)

**G. Other Agents for Non-Enzymatic Dissolution of Hyaloid Interface:**

15 As summarized hereabove, any of the above formulations containing urea or a urea derivative may be administered by intravitreal injection or otherwise caused to distribute into the vitreous or posterior segment of the eye in therapeutic concentrations, to cause non-enzymatic dissolution of the hyaloid membrane, thereby inducing PVD. As an alternative to, or in combination with, urea or a urea derivative, these formulations may contain other  
 20 compounds capable of causing non-enzymatic dissolution of the hyaloid membrane such as non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytidine, guanine, guanidine, guanidinium, guanidinium, thymidine, thimidine, uridine, uracil, cystine), uric acid, calcium acetal salicylate and ammonium sulfate. For example, a guanidinium preparation of the following formulation may be  
 25 administered by intravitreal injection, to deliver a dose of approximately 30micrograms to 5 milligrams, and preferably about 2mg. The injectate volume in which each such intravitreal dose is delivered is preferably about 50miroliters per injection. As a result of one or more intravitreal injections of this guanidinium preparation, the hyaline membrane will be substantially dissolved resulting in substantial PVD.

30

**Example 33**

Guanidinium HCL	0.01%-15.0%
Sodium Chloride USP/NF	up to 0.9%
Sterile Water for Injection USP	Q.S. 100%

pH of solution 5.0- 7.0

(Adjust pH using 0. 1 N Hydrochloric acid 0. 1 N Sodium Hydroxide)

It is to be appreciated that the invention has been described hereabove with  
5 reference to certain presently preferred embodiments and examples only, and no effort has  
been made to exhaustively describe all possible embodiments and examples wherein urea  
containing solutions (e.g. urea or hydroxy urea solutions) and/or solutions containing  
compounds capable of inducing non-enzymatic dissolution of the hyaloid membrane are  
used in accordance with the present invention. It is intended that all possible embodiments  
10 and examples of such solutions and the above-stated uses thereof, be included within the  
scope of following claims:

**CLAIMS**

What is claimed is:

1           1. A method for i) treating or preventing the proliferation of fibroblasts within the eye,  
2       ii) treating or preventing neovascularization of ocular tissues, iii) accelerating the clearance  
3       of hemorrhagic blood from the vitreous humor iv) causing non-enzymatic dissolution of the  
4       hyaloid interface and/or iv) causing posterior vitreous detachment or disinsertion, said  
5       method comprising the steps of:

6           A.     delivering into the posterior segment of the eye a therapeutically  
7       effective amount of an agent selected from the group consisting of;  
8                          urea;  
9                          a urea derivative;  
10                         a non-steroidal anti-inflammatory agent;  
11                         an antimetabolite;  
12                         a compound capable of causing non-enzymatic  
13                         dissolution of the hyaloid membrane; and,  
14                         possible combinations thereof.

1           2. A method according to Claim 1 wherein said agent is delivered into the posterior  
2       segment of the eye by intravitreal injection.

1           3. A method according to Claim 1 wherein the agent delivered in Step a contains a  
2       urea derivative selected from the group consisting of:  
3                          hydroxyurea;  
4                          thiourea; and,  
5                         possible combinations thereof.

1           4. A method according to Claim 1 wherein the agent delivered in Step A is an agent  
2       capable of causing non-enzymatic dissolution of the hyaloid membrane, said agent being  
3       selected from the group consisting of:  
4                  urea;  
5                  urea derivatives;  
6                  hydroxyurea;  
7                  thiourea;

8                   non-enzymatic proteins;  
9                   nucleosides;  
10                  nucleotides;  
11                  adenine;  
12                  adenosine;  
13                  cytosine;  
14                  cytadine;  
15                  guanine;  
16                  guanitadine;  
17                  guanidinium;  
18                  thymidine;  
19                  thimitadine;  
20                  uridine;  
21                  uracil;  
22                  cystine;  
23                  uric acid;  
24                  calcium acetal salicylate;  
25                  ammonium sulfate;  
26                  combinations thereof.

1                 5. A method according to Claim 3 wherein the agent delivered in Step a comprises  
2                 30 micrograms - 7500 micrograms of urea per 50 microliters to 100 UL of solution.

1                 6. A method according to Claim 5 wherein the solution delivered in Step a comprises  
2                 approximately 300 micrograms of urea per 50 microliters of solution.

3                 7. A method according to Claim 3 wherein Step a delivers a dose of 0.01% to 15.0%  
4                 urea into the vitreous body of the eye.

1                 8. A method according to Claim 1 wherein the solution delivered in Step a comprises  
2                 a solution that contains at least one agent selected from the group consisting of:  
3                   urea;  
4                   hydroxyurea;  
5                   thiourea;

mitomycin C; and, flurbiprofen.

1        9. A method according to Claim 1 wherein Step a comprises delivering into the  
2 posterior segment of the eye a therapeutically effective amount of a solution comprising i)  
3 urea and/or urea derivatives or mixtures thereof and ii) at least one non-steroidal anti-  
4 inflammatory agent.

- 1                10. A method according to Claim 9 wherein the non-steroidal anti-inflammatory agent
- 2 contained in the solution is selected from the group consisting of:
  - 3                flurbiprofen;
  - 4                diclofenac; and,
  - 5                ketorolac.

1        11. A method according to Claim 1 wherein Step a comprises delivering into the  
2 posterior segment of the eye a therapeutically effective amount of a solution comprising i)  
3 urea and/or urea derivatives or mixtures thereof and ii) at least one antimetabolite.

1           12. A method according to Claim 1 wherein the agent is an antimetabolite selected  
2 from the group consisting of:

3 mitomycin C;  
4 methotrexate;  
5 6-mercaptopuri  
6 thioguanine;  
7 5-fluorouracil;  
8 cytosine arabin  
9 5-azacytidine;  
10 hydroxyurea;  
11 thiourea; and,  
12 possible combin

13. A method according to Claim 1 wherein the agent delivered in Step A comprises 2000 micrograms of urea and 2000 micrograms of antimetabolite hydroxyurea, or 5.0 microgram of mitomycin C per 50 microliters of solution.

1           14. A method according to Claim 1 wherein the agent delivered in Step a comprises  
2     approximately 300 micrograms of urea and approximately 2000 micrograms of hydroxyurea,  
3     or 10 micrograms mitomicyn C per 50 microliters of solution.

1           15. A method according to Claim 1 wherein Step A is repeated a plurality of times  
2     and each performance of Step a delivers a dose of 2000 micrograms urea and a dose of 5.0  
3     micrograms of an anti-metabolite mitomicyn C or an antimetabolite.

1           16. A method according to Claim 1 wherein the method is performed for a purpose  
2     selected from the group consisting of;  
3               inducing posterior vitreous detachment and/or disinsertion of the vitreous body from  
4     the retina and epiretinal membranes (hereinafter referred to as "PWD");  
5               causing non-enzymatic dissolution of the hyaloid membrane;  
6               causing liquefaction of the vitreous humor;  
7               causing diffusion or preventing the accumulation of localized concentrations near the  
8     retina of substances that are injurious or pathogenic to the retina (e.g., angiogenic factors);  
9               causing dissolution of coagulum within the vitreous humor (as may occur following  
10   intravitreal hemorrhage);  
11              causing a solvent action on fibroblasts;  
12              inhibiting fibroblasts;  
13              inhibiting or preventing fibrosis associated with the presence of vitreous heme;  
14                inhibiting the proliferation of fibroblasts in ocular tissues.  
15              treating (e.g., preventing, deterring, stopping or slowing the progression of) diabetic  
16   retinopathy;  
17              treating intravitreal hemorrhage and accelerating the clearance of hemorrhagic blood  
18   from the vitreous humor;  
19              inducing PVD and/or liquefaction of the vitreous prior to the performance of a  
20   vitrectomy thereby limiting the likelihood of retinal detachment, retinal tearing, re-stimulation  
21   of retinal hemorrhage or other complications of the vitrectomy procedure;  
22              treating vitreous traction associated with macular holes;  
23              treating macular degeneration;  
24              treat retinitis pigmentosa;  
25              prophylaxis to retinal detachment in patients who are at high risk for retinal  
26   detachment (e.g, high myopes);

27       treating preretinal and subretinal membranes;  
28       treating cystoid macular edema;  
29       pre-operative preparation of the eye in the surgical treatment of eye trauma;  
30       pre-operative treatment prior to certain types of glaucoma surgery (e.g., those  
31      performed for the treatment of neovascular glaucoma);  
32       treating occlusion of the central retinal vein or central retinal artery;  
33       treating conditions associated with neovascularization such as neovascular iris and  
34      neovascular glaucoma;  
35       treating ocular ischemic syndrome;  
36       treating conditions associated with posterior eye inflammation such as VKH, pars  
37      planitis, toxoplasmosis, etc.; and,  
38       improving the delivery and bioavailability to the retina and other tissues of intravitreally  
39      administered drugs.

1           17. A method according to Claim 1 wherein said agent is delivered into the posterior  
2      segment of the eye by initially administering the agent to the anterior segment of the eye in  
3      a form and dose that is sufficient to cause a therapeutic amount of the agent to distribute to  
4      the posterior segment.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/05587

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) :A61K 31/70, 31/60, 31/495, 31/40, 31/195, 31/19, 31/17

US CL :514/45, 46, 49, 50, 159, 249, 411, 413, 567, 570, 580, 588

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/45, 46, 49, 50, 159, 249, 411, 413, 567, 570, 580, 588

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,110,493 A (CHERNG-CHYI et al) 05 May 1992, see the claims in particular.	1-17
Y	US 5,441,984 A (HEATH, JR. et al) 15 August 1995, see the claims in particular.	1-17
Y	US 5,554,187 A (RIZZO, III) 10 September 1996, see entire patent.	1-17
Y, P	US 5,891,084 A (LEE) 06 April 1999, see entire patent.	1-17
Y, P	US 5,891,913 A (SALLMANN et al) 06 April 1999, see the claims in particular.	1-17

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

13 JUNE 2000

Date of mailing of the international search report


13 JUL 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230

Authorized officer

WILLIAM JARVIS

Telephone No. (703) 308-1235



**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US00/05587

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

BRS - WEST

search terms: hydroxyurea, thiourea, urea, mitomycin C, flurbiprofen, diclofenac, ketorolac, eye, ocular, ophthalmic, vitreous, hyaloid, retina, retinopathy, retinitis, macular degeneration, etc.